Grifols, S.A. Q1 2026 Earnings Recap

Shares declined 1.2% following the quarter, reflecting investor caution despite results largely in line with prior guidance and steady margins, with market focus likely on the cautious outlook and incremental execution challenges ahead. The market reaction suggests investors remain cautious on the outlook and any incremental pressure on margin expansion or growth acceleration.

Key Takeaways

• Revenue reached EUR 1.7 billion, up 3.3% at constant currency, driven primarily by a nearly 7% growth in the Biopharma segment, notably from the immunoglobulin franchise.
• Adjusted EBITDA stood at EUR 404 million (constant currency), with margins broadly stable year-over-year, signaling no immediate margin expansion despite strategic efforts.
• Free cash flow improved by EUR 30 million, with leverage stable at 4.3x, consistent with typical seasonal patterns.
• The company confirmed ongoing execution of five strategic pillars, including ramping up its Egypt plasma platform to reduce sourcing costs and optimize the global plasma supply chain.
• Diagnostics revenue declined on a reported basis due to the dissolution of a joint venture, though underlying business showed low single-digit growth on a like-for-like basis.